CN1726960A - Combination of effective parts for curing chronic hepatitis, preparation and usage - Google Patents
Combination of effective parts for curing chronic hepatitis, preparation and usage Download PDFInfo
- Publication number
- CN1726960A CN1726960A CN 200410041495 CN200410041495A CN1726960A CN 1726960 A CN1726960 A CN 1726960A CN 200410041495 CN200410041495 CN 200410041495 CN 200410041495 A CN200410041495 A CN 200410041495A CN 1726960 A CN1726960 A CN 1726960A
- Authority
- CN
- China
- Prior art keywords
- radix
- compositions
- radix bupleuri
- total
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of tablet, capsule, softgel, pill, etc for treating chronic hepatism and chronic hepatitis is prepared from bupleurum root, scutellaria root and liquorice root through extracting their active components, mixing them with proper excipient, and shaping.
Description
Technical field:
The invention belongs to Chinese medicine development field, relate to a kind of active component composition and preparation and purposes for the treatment of chronic hepatitis, be specifically related to active component composition that a kind of Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides that extracts form and preparation thereof and have application in the medicine of hepatitis virus resisting, the liver protecting and ALT lowering, adjusting immunologic function from Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor Chinese crude drugs in preparation.
Background technology:
Chronic hepatitis is meant that inflammation, histology and the biochemical unusual sign of liver continue to surpass 6 months, and the state of an illness does not have and is clearly better, or activeness inflammatory activity person is arranged in the liver.It is not a single disease, but comprises the chronic hepatopathy due to the various causes of disease.Chronic hepatitis can be caused by reasons such as virus, medicine, ethanol.The ACAH chronic hepatopathy can be caused that promptly claim ACAH, the cause of disease of primary disease is not too clear and definite, and tangible autoimmune phenomena is arranged by the another kind of cause of disease, therefore thinks that this is important pathogeny.Motherland's traditional medicine think chronic hepatitis mainly be damp and hot evil poison invasion with healthy energy impaired due to.It is chronic hepatitis morbidity and the pathogenesis that produces various clinical diseases that the touching difficulty of damp is dispelled.For chronic hepatitis treatment, doctor trained in Western medicine is many based on general treatment and Drug therapy.Wherein how Drug therapy is based on comprehensive medication, and used medicine mostly is antivirus action, temporarily suppresses virus replication, stops effects such as albumen, DNA synthesize.But the toxic and side effects of Western medicine is very big, is unfavorable for taking for a long time." liver " of the traditional Chinese medical science all has regulating action " system " to the whole body yang blood and qi.Thereby in treatment, not only will control from the liver opinion, also to control from negative and positive of qi and blood or its dirty opinion, could reflect that the traditional Chinese medical science is careful because of discussing the characteristic of controlling.Because the chronic hepatitis course of disease is longer, state of an illness complexity, and main pathogenic factor is that damp and hot malicious evil invasion is impaired with healthy energy, many opinions are executed and are controlled from heat-clearing and toxic substances removing dampness removing, blood circulation promoting and blood stasis dispelling, enriching yin boost qi legislation.Therefore, motherland's medical science focuses on dialectical opinion and controls the treatment of primary disease, also pays attention to the adjusting of body autoimmune function in treatment, really is the effect that has reached treating both the principal and secondary aspects of a disease.
In recent years, the Chinese medicine preparation of relevant treatment chronic hepatitis, chronic hepatopathy emerges in an endless stream, and the treatment of hepatitis, hepatopathy is had certain curative effect.But these medicines mostly are the compound preparation of number flavor even tens of flavor Chinese medicines.It goes into various, the complicated component of flavour of a drug number, and because the technology of making is simple, and the used composition that is used as medicine mostly is powder, crude extract or even some prepared slices of Chinese crude drugs of crude drug, difficult quality control.We are through the retrieval to Chinese patent information, the patent that mostly is some big compound recipes that inquires, for example application number is 95113729.8 " hepatitis B health Chinese medicinal capsule ", application number is 96118901.0 " convalescence capsule for hepatosis patient ", the patent No. is 01128113.8 " a kind of medicine for the treatment of hepatopathy " etc., not about be used for the treatment of hepatitis, hepatopathy as the main component of medicine with " effective part group ".We are by a large amount of prescription screenings, the side's of tearing open research, according to theory of Chinese medical science is guideline, with Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor Chinese medicines prescription again, and employing modern Chinese medicine extraction process, extract the effective site of refining above-mentioned three flavor medical materials, it is combined into the treatment that effective part group is used for hepatopathy.Inquiry through relevant information, pharmaceutical manufacturer or medical research organisations do not extract effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides composition effective part group with regard to Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae both at home and abroad, and production and processing becomes the treatment that the appropriate drug preparation is used for hepatopathy.
Summary of the invention:
The present invention is directed to the deficiencies in the prior art, provide a kind of effective site Radix Bupleuri total glycosides that from Chinese crude drug Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae, extracts, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides to form effective part group, so that make the synergism of the more powerful treatment chronic hepatitis of the composition performance of hepatitis virus resisting, the liver protecting and ALT lowering, adjusting immunologic function in the three flavor medical materials.
Further purpose of the present invention is to provide a kind of effective part group production and processing that the effective site of above-mentioned three flavor medicinal material extract is made up, with its medicine that cures mainly chronic hepatitis and preparation thereof as hepatitis virus resisting, the liver protecting and ALT lowering, adjusting immunologic function.
At first, the active component of the medicine of hepatitis virus resisting provided by the invention, the liver protecting and ALT lowering, adjusting body's immunity is the compositions of effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides that derives from Chinese crude drug Radix Bupleuri, Radix Scutellariae and the Radix Glycyrrhizae of certain proportion (this ratio see hereinafter describe), be effective part group, wherein the actual content of effective site summation is not less than 70% of total extract.
Secondly, the active component of the medicine of hepatitis virus resisting provided by the invention, the liver protecting and ALT lowering, adjusting body's immunity be Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor medical materials contained effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides according to a certain percentage (this ratio sees hereinafter and describes) combine.Also can become effective part group with baicalin, glycyrrhizin and Radix Bupleuri total glycosides extract combination.Therefore, these three kinds of chemical compounds no matter be plant extract or derive from chemosynthesis, may be used among the active component of the present composition.
Once more, the invention allows for the preparation method of effective part group.Its preparation route is that above-mentioned three flavor Chinese crude drugs are extracted active component according to the above ratio respectively, promptly from the Radix Glycyrrhizae crude drug, extract Radix Glycyrrhizae total glucosides, from the Radix Bupleuri crude drug, extract Radix Bupleuri total glycosides, from the Radix Scutellariae crude drug, extract Radix Scutellariae total flavones, then these effective sites of gained are combined into effective part group according to certain ratio; Also can be from the Radix Bupleuri crude drug, to extract Radix Bupleuri total glycosides and baicalin, glycyrrhizin are combined into effective part group according to certain ratio.
The medicine of hepatitis virus resisting of the present invention, the liver protecting and ALT lowering, adjusting body's immunity is promptly gone up the suitable pharmaceutical excipient of acceptable by above-mentioned effective part group and physiology and is formed.Dosage form of the present invention is mainly oral formulations, comprises tablet such as ordinary tablet, slow releasing tablet, controlled release tablet, dispersible tablet, oral cavity disintegration tablet etc. and hard capsule, soft capsule, pill, granule, oral liquid etc.
Compositions of the present invention can be used as the medicine and prognosis treatment, auxiliary treatment and the long-term treatment medicine of above-mentioned disease after acute stage of chronic hepatopathy, chronic hepatitis.
Following detailed will help further to understand the present invention.
Unless otherwise indicated, the part term of this description is defined as follows:
Radix Bupleuri: or its crude drug, be the root of umbelliferae bupleurum (Bupleurum chinense DC), or the tcm and herbal slice of making by its dry root.The Radix Bupleuri beginning is stated from " herbal classic ", classifies as top grade.Its bitter in the mouth, suffering, cold nature, the master goes into Liver Channel, is the key medicine of hepatopathy, and " curing mainly secret wanting " cloud: shaoyang channel is divided medicine." book on Chinese herbal medicine justice ": " pact, Radix Bupleuri cures mainly, and only has two layers: one is the domination of pathogen, then be exopathogen the half exterior and half interior person, draw it, make to reach in table and exopathogen is spontaneous; One is weakened body resistance, then for clearing heat in QI system sink into cloudy branch person, lift and rise it, make and return its residence, and middle gas self-vibration." used among the present invention be the root of plant Radix Bupleuri, in use can be with its section or pulverizing so that extract.
Radix Scutellariae: or its crude drug, be the root of labiate (Scutellaria baicalensis G), or the tcm and herbal slice of making by its dry root.Radix Scutellariae is recorded in Shennong's Herbal the earliest, and its bitter in the mouth yellow skin and gas are cold, bitter can dampness, but cold heat clearing away, yellow skin and go into Central Region, thus Jiao's heat in being longer than clearly, dry in burnt wetting, " all heat of master, jaundice ... .. is relieved oedema or abdominal distension through diuresis or purgation, hematochezia closes." think that Radix Scutellariae " is apt to again into the liver and gall heat clearing away, controls few positive alternate attack of chill and fever " in " Records of Tradition Chinese and Western Medicine in Combination ".What the present invention used is the root of Radix Scutellariae, and with its section or pulverizing so that extract.
Radix Glycyrrhizae: or its crude drug, be root or the rhizome of glycyrrhizic legume (Glycyrrhiza uralensis Fisch), or the tcm and herbal slice of making by its dry root.The Radix Glycyrrhizae sweet in the mouth, property is flat, and " qualcomm meridian, sharp vim and vigour, the merit of separating hundred poison, coordinating the actions of various ingredients in a prescription " knownly since ancient times arranged; " book on Chinese herbal medicine newly organized ": " the Radix Glycyrrhizae detoxifcation, when a minute upper, middle and lower three therapeutic methods of traditional Chinese medicine, on rule the poison of the part of the body cavity above the diaphragm housing the heart and lungs by law, should draw and tell it, Jiao's poison in the middle ruling by law, should with and separate it.Purgation is controled the inferior Jiao's poison, rushes down it when pursuing." what use among the present invention is the root of Radix Glycyrrhizae, and with its section or pulverizing so that extract.
Radix Bupleuri total glycosides: be meant the saponins material that from the Radix Bupleuri crude drug, extracts, and wherein total saponin content is not less than 50% (w/w) of total extract.
Radix Scutellariae total flavones: be meant the Flavonoid substances that from the Radix Scutellariae crude drug, extracts, and wherein Radix Scutellariae total flavones content is not less than 80% (w/w) of total extract.
Radix Glycyrrhizae total glucosides: be meant the glycyrrhizin class material that from the Radix Glycyrrhizae crude drug, extracts, and its content is not less than 80% (w/w) of total extract.
Effective part group: be meant in the present invention and extract the compositions that effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides are formed from Chinese crude drug Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae, the actual content of effective part group is not less than 70% of total composition in the said composition; Effective part group also comprises in the above-mentioned active component composition compositions that the pure product that add extraction separation comes out from above-mentioned three flavor crude drugs of the same type pure product or chemosynthesis are formed according to the proportion of hereinafter describing.The actual content sum of each effective site also all is not less than 70% of total composition in all these effective part groups.
The present composition comprises that above-mentioned effective part group and physiology go up the acceptable pharmaceutical excipient.Wherein the composition of effective part group and preparation method are as follows: origin comes from the effective part group of effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and the Radix Glycyrrhizae total glucosides composition of Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae crude drug in specific " proportion ", the proportion (w/w/w) of three flavor medical materials is between 40: 5: 1 to 1: 1: 1, preferred proportion is between 20: 3: 1 to 10: 5: 3, and best proportion is 5: 2: 1.Effective component extracting from above-mentioned three flavor medical materials, and through separation and purification, refining effective site Radix Bupleuri total glycosides, Radix Scutellariae total flavones and the Radix Glycyrrhizae total glucosides that reaches the effective ingredient enrichment is " effective part group " with the effective site combination again; Also can be from crude drug Radix Bupleuri, to extract the effective site Radix Bupleuri total glycosides, be combined into effective part group according to a certain percentage with baicalin, glycyrrhizin again.Wherein the ratio (w/w) of baicalin, glycyrrhizin and Radix Bupleuri total glycosides extract total amount is respectively between 8: 1 to 1: 1 and 1: 20 to 2: 1, preferred proportion (w/w) is between 4: 1 to 6: 5 and 1: 10 to 3: 5, and best proportion (w/w) was respectively 3: 1 and 2: 5.The solvent that is used for extracting or extract usefulness among the preparation technology can be water, ethanol, methanol, n-butyl alcohol, ethyl acetate, petroleum ether and other organic solvent.In addition, above-mentioned effective part group both can be to derive from plant (Chinese crude drug) to extract, and also can derive from chemosynthesis or semi-synthetic.
The present invention also proposes to go up the Pharmaceutical composition that the acceptable pharmaceutical excipient is formed by above-mentioned " effective part group " and physiology.The dosage form of these Pharmaceutical compositions is mainly oral formulations, comprises tablet such as ordinary tablet, slow releasing tablet, controlled release tablet, dispersible tablet, oral cavity disintegration tablet etc. and hard capsule, soft capsule, pill, granule, oral liquid etc.
This product is compared with prior art has following advance, novelty: at first, from the compatibility of drugs aspect, this product is under the guidance of theory of Chinese medical science, to hundreds of medicine screen, optimum organization, finally determine to carry out compatibility by three flavor Chinese medicines, Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI, yang invigorating induce sweat in the side; The invigorating middle warmer of Radix Glycyrrhizae QI invigorating, relieving spasm to stop pain; Radix Scutellariae heat clearing and damp drying, eliminating fire and detoxication, three medicines share the effect of playing treating both the principal and the secondary aspects of a disease at the same time; Secondly, the present invention is combined into effective part group with Radix Bupleuri total glycosides, Radix Scutellariae total flavones and three effective sites of Radix Glycyrrhizae total glucosides with suitable ratio optimization first, wherein Radix Bupleuri total glycosides 〉=50%; Radix Scutellariae total flavones 〉=80%; Radix Glycyrrhizae total glucosides 〉=80%, effective part group in the compositions 〉=70%.This effective part group and each effective site thereof are carried out qualitative and quantitative analysis by modern analysis methods such as high-efficient liquid phase analysis method, uv analysis method, thin layer chromatographies and detected, and is quality controllable.Be used as medicine with this effective part group, the definite ingredients of being used as medicine, it is lower to have remedied present compound Chinese medicinal preparation scientific and technological content, and active constituent content is low or indeterminate, shortcomings such as difficult quality control; The 3rd, from the drug effect aspect, this product is that three effective sites of distinguishing the flavor of medical materials are combined into effective part group according to suitable ratio proportioning, with the main component of this effective part group as medicine, the full side of three herbal medicines cooperates, and has avoided the one-sidedness of single curative effect of medication, has strengthened the effect of medicine hepatitis virus resisting greatly, also having the effect of the liver protecting and ALT lowering, adjusting immunologic function simultaneously, is the natural drug that cures mainly a new generation of chronic hepatitis, chronic hepatopathy.
Description of drawings:
Fig. 1 is the process chart of embodiment 1;
Fig. 2 is the process chart of embodiment 2;
Fig. 3 is the experimental result to the influence of Rats with Acute Liver Injury SGPT activity (u/100ml);
Fig. 4 is the result of experiment to the influence of Rats with Acute Liver Injury SGOT activity (u/100ml);
Fig. 5 is the experimental result to the influence of macrophage phagocytic effect;
Fig. 6 is the experimental result to the excretory influence of rat bile.
The invention will be further described by the following examples, but be not limited in this.
Specific embodiment:
Embodiment 1
Get the effective part group that a certain proportion of Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides are formed, drying, pulverizing, mistake 80 mesh sieves are crossed 80 mesh sieve mix homogeneously with microcrystalline Cellulose, ethanol system granule with 95%, forced air drying is with 20 mesh sieve granulate, the fill capsule, the polishing packing gets final product.
Prescription is formed (1000) Radix Bupleuri total glycosides 30g
Radix Scutellariae total flavones 70g
Radix Glycyrrhizae total glucosides 50g
Microcrystalline Cellulose 75g
Figure of description 1 is seen in its technological process.
Embodiment 2
Get the effective part group that a certain proportion of Radix Bupleuri total glycosides, baicalin and glycyrrhizin are formed, drying, pulverizing, mistake 80 mesh sieves are crossed 80 mesh sieve mix homogeneously with microcrystalline Cellulose, carboxymethyl starch sodium, with 5%PVP system granule, forced air drying is with 20 mesh sieve granulate, add magnesium stearate, tabletting.
Prescription is formed: (1000) Radix Bupleuri total glycosides 10g
Baicalin 30g
Glycyrrhizin 4g
Carboxymethyl starch sodium 5g
Microcrystalline Cellulose 73g
Magnesium stearate 2g
Figure of description 2 is seen in its technological process.
Illustrate its drug action with The pharmacological results below:
One, to the influence of D-Gal amine Rats with Acute Liver Injury SGPT and SGOT:
Experimental technique:
Get body weight 80 of the Wistar of 250-300g inbred line rats, the male and female dual-purpose, be divided into 4 groups (negative control group, protect the liver I group, protect the liver II group, liver-protecting tablet group) at random, the administration group is successive administration 3 days once a day, negative control group is given the isometric(al) normal saline, fasting before the experiment, the 4th day lumbar injection GalN600mg/kg, in injection 48 hours, 120 hours, 672 hours behind the GaIN, randomly draw respectively and respectively organize 1/3 animal, heart extracting blood, separation of serum are measured SGPT and SGOT on automatic biochemistry analyzer.Experimental result is represented with x ± sd.
Experimental result:
This product can significantly reduce SGPT, the SGOT level that D-Gal amine causes the Rats with Acute Liver Injury model, and prompting this product has more significantly the effect that protects the liver, falls enzyme, hepatoprotective.
Experimental result to the influence of Rats with Acute Liver Injury SGPT activity (u/100ml) sees Fig. 3 for details, annotates: with the normal saline group relatively
*P＜0.05,
*P＜0.01;
Experimental result to the influence of Rats with Acute Liver Injury SGOT activity (u/100ml) sees Fig. 4 for details, annotates: with the normal saline group relatively
*P＜0.05,
*P＜0.01.
Two, to the influence of macrophage phagocytic effect:
Experimental technique:
Get 60 of Kunming mouses and be divided into 3 groups of (normal saline groups at random, protect the liver the I group, protect the liver the II group), administration group successive administration 3 days, matched group is given the isometric(al) normal saline, 2 hours every mouse peritoneals are injected 5% chicken red blood cell 0.4ml after the last administration, after 12 hours animal are taken off cervical vertebra and put to death, and face upward the position and are fixed on the Mus plate, skin is cut off in the abdominal part sterilization, inject normal saline 2ml, rotational fixation plate 1min extracts abdominal cavity washing liquid 1ml then, drip and be applied on the clean slide, every 0.2ml, places the enamel box that is lined with wet gauze by totally two, put into 37 ℃ of incubator incubation 30min, take out slide, drop into rinsing in the normal saline, to remove the not cell of paster.Dry, with the fixing 5min of acetone-methanol solution (1: 1), reuse 4% Ji Mu Sa-Rui Teshi liquid dyeing 5min, the distilled water rinsing is dried.Put 200 macrophages of every meter under the oily mirror, calculate phagocytic index and phagocytic percentage.Experimental result is represented with x ± sd.
Experimental result:
This product can significantly strengthen the phagocytosis of macrophage, and showing has immunological enhancement preferably.
Experimental result sees Fig. 5 for details, annotates: compare with the normal saline group
*P＜0.01.
Three, to the excretory influence of rat bile:
Experimental technique:
40 of extracting male Wistar rats, be divided into 4 groups (normal saline groups, protect the liver I group, protect the liver II group, dehydrocholic acid group) at random by body weight, during experiment with behind the pentobarbital sodium 60mg/kg intraperitoneal injection of anesthesia, facing upward the position is fixed on the rat Mus plate, cut about 2cm along the abdomen median line, open the abdominal cavity, the upset duodenum is worn two rhizoid lines, the ligation pars papillaris under bile duct, make one " V " shape otch to the liver direction, insert plastic tube, ligation fixed plastics pipe is collected bile with small beaker, used after operation hemostasis clamp closes stomach wall, and saline gauze covers.After stablizing 20min, collect the bile of 30min earlier, the rat of administration group then gives medicinal liquid by duodenum, negative control group gives to wait the normal saline of capacity, collects once totally three times after the administration every 30min, the record bile flow, bile flow increases percentage rate after the calculating administration.Experimental result is represented with x ± sd.
Experimental result:
Compare with the normal saline group, this product can significantly increase bile flow, and prompting this product has good choleretic effect.
Experimental result sees Fig. 6 for details, annotates: compare with the normal saline group
*P＜0.01.
Claims (13)
1. one kind is mainly used in the active component composition for the treatment of chronic hepatitis, " effective part group " and the physiology that it is characterized in that comprising the effective site combination with hepatitis virus resisting, the liver protecting and ALT lowering, adjusting immunologic function of extracting from Chinese crude drug Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae go up acceptable pharmaceutical excipient, and wherein " effective part group " is:
(1) from a certain proportion of above-mentioned three flavor crude drugs, extracts the compositions that Radix Bupleuri total glycosides, Radix Scutellariae total flavones and Radix Glycyrrhizae total glucosides are composited;
(2) compositions of forming according to a certain percentage by Radix Bupleuri total glycosides and baicalin, glycyrrhizin.
2. according to the compositions of claim 1, it is characterized in that the actual content of effective part group is not less than 70% of total extract.
3. according to the compositions of claim 1, it is characterized in that this effective part group is the compositions of the Radix Bupleuri total glycosides, Radix Scutellariae total flavones and the Radix Glycyrrhizae total glucosides that extract from Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor crude drugs.
4. according to the compositions of claim 3, the usage ratio (w/w/w) of Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor crude drugs that it is characterized in that being used to extract effective site is between 40: 5: 1 to 1: 1: 1.
5. according to the compositions of claim 4, the usage ratio (w/w/w) of Radix Bupleuri, Radix Scutellariae and Radix Glycyrrhizae three flavor crude drugs that it is characterized in that being used to extract effective site is between 20: 3: 1 to 10: 5: 3.
6. according to the compositions of claim 5, the usage ratio (w/w/w) that it is characterized in that being used to extract Radix Bupleuri, Radix Scutellariae and the Radix Glycyrrhizae three flavor crude drugs of effective site is 5: 2: 1.
7. according to the compositions of claim 1, it is characterized in that the compositions that this effective part group can be made of according to a certain percentage Radix Bupleuri total glycosides and baicalin, glycyrrhizin.
8. according to the compositions of claim 7, the usage ratio (w/w) that it is characterized in that the baicalin, glycyrrhizin and the Radix Bupleuri total glycosides that wherein add is respectively between 8: 1 to 1: 1 and 1: 20 to 2: 1.
9. compositions according to Claim 8, the usage ratio (w/w) that it is characterized in that the baicalin, glycyrrhizin and the Radix Bupleuri total glycosides that wherein add is respectively between 4: 1 to 6: 5 and 1: 10 to 3: 5.
10. according to the compositions of claim 9, it is characterized in that the usage ratio (w/w) of the baicalin, glycyrrhizin and the Radix Bupleuri total glycosides that wherein add was respectively 3: 1 and 2: 5.
11., it is characterized in that the application in the medicine of preparation hepatitis virus resisting, the liver protecting and ALT lowering, adjusting immunologic function according to the compositions of claim 1.
12. according to the compositions of claim 1, it is characterized in that in this effective part group, adding other effective ingredient, effective site, synthetic or suitable pharmaceutical excipient, be prepared into suitable pharmaceutical dosage form.
13. dosage form according to the compositions of claim 12, it is characterized in that said dosage form mainly is an oral formulations, comprises tablet such as ordinary tablet, slow releasing tablet, controlled release tablet, dispersible tablet, oral cavity disintegration tablet etc. and hard capsule, soft capsule, pill, granule, oral liquid etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410041495 CN1726960A (en) | 2004-07-27 | 2004-07-27 | Combination of effective parts for curing chronic hepatitis, preparation and usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410041495 CN1726960A (en) | 2004-07-27 | 2004-07-27 | Combination of effective parts for curing chronic hepatitis, preparation and usage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1726960A true CN1726960A (en) | 2006-02-01 |
Family
ID=35926599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410041495 Pending CN1726960A (en) | 2004-07-27 | 2004-07-27 | Combination of effective parts for curing chronic hepatitis, preparation and usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1726960A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981779B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Xanthosine composition and its production method |
| CN101590105B (en) * | 2008-05-30 | 2012-10-31 | 财团法人工业技术研究院 | Chinese medicinal herb extract for inducing immune cells to generate interferon and activated TOLL-like receptors and preparation method thereof |
| CN105250361A (en) * | 2015-11-27 | 2016-01-20 | 史克勇 | Traditional Chinese medicine composition capable of protecting liver |
| CN110123872A (en) * | 2019-06-14 | 2019-08-16 | 南京博源医药科技有限公司 | A kind of medicament and preparation method thereof for treating hepatitis |
-
2004
- 2004-07-27 CN CN 200410041495 patent/CN1726960A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981779B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Xanthosine composition and its production method |
| CN101590105B (en) * | 2008-05-30 | 2012-10-31 | 财团法人工业技术研究院 | Chinese medicinal herb extract for inducing immune cells to generate interferon and activated TOLL-like receptors and preparation method thereof |
| CN105250361A (en) * | 2015-11-27 | 2016-01-20 | 史克勇 | Traditional Chinese medicine composition capable of protecting liver |
| CN110123872A (en) * | 2019-06-14 | 2019-08-16 | 南京博源医药科技有限公司 | A kind of medicament and preparation method thereof for treating hepatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Reflections on treatment of COVID-19 with traditional Chinese medicine | |
| CN1742939B (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN1317027C (en) | Chinese medicine for treating depression | |
| CN100531771C (en) | Medicine for treating chronic pelvic inflammation and its preparation method | |
| CN101129593A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
| CN1899342A (en) | Oral medicine for treating diabetes and its use | |
| CN101134085A (en) | Traditional Chinese medicine for treating apoplectic hemiplegia | |
| CN101152385A (en) | Traditional Chinese medicine for treating acute suppurative otitis media | |
| CN101129636A (en) | Medicine for treating nasal inflammation | |
| CN105311069A (en) | Traditional Chinese medicine composition for reducing blood lipid and protecting livers | |
| CN101584759B (en) | Pharmaceutical composition with pure plant origin and application thereof | |
| CN101549016B (en) | Traditional Chinese medicine composition for treating acute and chronic pharyngitis and preparation method thereof | |
| CN101085231A (en) | Internal-applied traditional Chinese medicine composition for treating depression | |
| CN105582124B (en) | Chinese medicinal composition for treating constipation, and its preparation method | |
| CN101933973A (en) | Medicament composition for preventing and treating liver damage | |
| CN1726960A (en) | Combination of effective parts for curing chronic hepatitis, preparation and usage | |
| CN111407808B (en) | Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN103768327B (en) | A kind of pure component Chinese medicine preparation and preparation technology treating functional dyspepsia | |
| CN100417410C (en) | Medicine for treating gastrointestinal summer damp cold and preparing method thereof | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN101143199A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN112168931B (en) | A pharmaceutical composition for treating oral ulcer, and its preparation method | |
| CN101129554A (en) | Traditional Chinese medicine for treating migraine | |
| CN1256923A (en) | Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |